Researchers using the AREDS lens grading scale have found that long-term clinically relevant outcomes can be predicted by 2-year changes in severity of lens opacities.
NICE has released a draft decision recognizing the benefits of aflibercept solution for injection for the majority of patients with visual impairment caused by DME.
Patients who receive triamcinolone acetonide treatment for DME demonstrate changes in OCT reflectivity in their foveal cystoid spaces that are associated with a rebound in macular thickening and visual deterioration.
The posterior retina is a site of oxytocin (OXT) activation of the oxytocin receptor (OXTR), according to a study published online.
The NHS is facing issues related to the diagnosing, treating and managing the growing number of ageing people affected by AMD, the leading cause of blindness in the Western world.
A proprietary retinal laser technology has demonstrated the potential to reverse the accumulation of drusen in patients with high-risk early AMD over a 24-month period.
Patients with polypoidal choroidal vasculopathy may benefit from intravitreal aflibercept.
Extensive pars plana vitrectomy and cataract extraction can significantly improve visual acuity in juvenile idiopathic arthritis patients suffering from severe ocular complications of uveitis.
Patients with diabetic macular oedema (DME) who received aflibercept injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to those who received either bevacizumab or ranibizumab.
There is a correlation between functional cell loss in the retina and signs of dementia in people who have a genetic risk for frontotemporal dementia (FTD), according to researchers from the US.